Fed’s Powell opens door to potential rate cuts at Jackson Hole
Stephen C. Evans, a director at Merit Medical Systems Inc. (NASDAQ:MMSI), recently sold 5,000 shares of the company’s common stock. The shares were sold on March 3, 2025, at a weighted average price of $105.31, amounting to a total transaction value of $526,550. The shares were sold in multiple transactions, with prices ranging from $105.07 to $105.71. Following this sale, Evans holds 4,657 shares directly. The transaction occurs as Merit Medical (TASE:BLWV), with a market capitalization of $6 billion, trades near its InvestingPro Fair Value, showing strong financial health with a "GREAT" overall score.
This transaction is part of routine insider trading disclosures required by the Securities and Exchange Commission, providing transparency into the trading activities of company insiders. According to InvestingPro analysis, Merit Medical maintains healthy financials with a current ratio of 4.27 and operates with moderate debt levels. For deeper insights into MMSI’s valuation and 12+ additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Merit Medical Systems Inc. reported its fourth-quarter 2024 earnings, which exceeded expectations with an earnings per share (EPS) of $0.93, surpassing the forecasted $0.82. The company’s revenue for the quarter reached $355.2 million, outperforming the anticipated $346.76 million, reflecting strong operational performance. Notably, Merit Medical’s gross margin improved by approximately 300 basis points year-over-year, marking its highest ever. Analysts from Raymond (NSE:RYMD) James raised the company’s stock price target to $116, noting the potential for Merit Medical to exceed its own forecasts. Oppenheimer and Needham also adjusted their price targets to $116, with both firms maintaining positive ratings on the stock despite the target revisions. Merit Medical’s recent acquisitions, including Cook Medical and EndoGastric Solutions, have been highlighted as performing beyond initial expectations. The company provided sales guidance for 2025, projecting organic growth of 5.5-6.5%, although EPS guidance was slightly lower due to accounting changes related to convertible securities. Additionally, Merit Medical’s free cash flow saw a significant year-over-year increase of 67%, totaling $185 million in 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.